An octadentate bis(semicarbazone) macrocycle: a potential chelator for lead and bismuth radiopharmaceuticals-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An octadentate bis(semicarbazone) macrocycle: a potential chelator for lead and bismuth radiopharmaceuticals

Published:2020 Issue:42 Volume:49 Page:14962-14974
ISSN:1477-9226
Container-title:Dalton Transactions
language:en
Short-container-title:Dalton Trans.

Author:

Lange Jaclyn L.¹²³⁴⁵,Davey Patrick R. W. J.⁶⁷⁸⁹^ORCID,Ma Michelle T.¹²³⁴⁵^ORCID,White Jonathan M.¹⁰¹¹¹²⁹^ORCID,Morgenstern Alfred¹³¹⁴¹⁵¹⁶¹⁷,Bruchertseifer Frank¹³¹⁴¹⁵¹⁶¹⁷,Blower Philip J.¹²³⁴⁵^ORCID,Paterson Brett M.⁶⁷⁸⁹¹⁸^ORCID

Affiliation:

1. School of Biomedical Engineering and Imaging Sciences

2. King's College London

3. St Thomas’ Hospital

4. London SE1 7EH

5. UK

6. School of Chemistry

7. Monash University

8. Clayton

9. Australia

10. School of Chemistry and Bio21 Molecular Science and Biotechnology Institute

11. The University of Melbourne

12. Melbourne

13. European Commission

14. Joint Research Centre

15. Directorate for Nuclear Safety and Security

16. 76125 Karlsruhe

17. Germany

18. Monash Biomedical Imaging

Abstract

A cyclen bearing semicarbazone pendant groups forms complexes with Bi³⁺ and Pb²⁺ and was radiolabeled with the alpha-emitting radioisotope ²¹³Bi.

Funder

Australian Research Council

State Government of Victoria

Cancer Research UK

Engineering and Physical Sciences Research Council

Publisher

Royal Society of Chemistry (RSC)

Subject

Inorganic Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2020/DT/D0DT02673E

Reference83 articles.

1. Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials

2. Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)

3. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience

4. The Development of the α-Particle Emitting Radionuclides 212Bi and 213Bi, and Their Decay Chain Related Radionuclides, for Therapeutic Applications

5. Targeted Alpha Therapy with 213Bi

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Theoretical Study of Metal–Ligand Interactions in Lead Complexes with Radiopharmaceutical Interest;Molecules;2024-09-04

2. Macrocyclic derivatives of imidazole as chromoionophores for bismuth(III)/lead(II) pair;Sensors and Actuators B: Chemical;2024-01

3. Molecular structure determination of Nickel(II) isomers bearing bis(thiosemicarbazone) ligands: X-ray, DFT calculations and kinetic groundwork;Journal of Molecular Structure;2024-01

4. Rapid and stable complexation of the α-generators bismuth-212 and lead-212 with a tetraazamacrocyclic chelator bearing thiosemicarbazone pendant arms;Inorganic Chemistry Frontiers;2024

5. Preclinical Evaluation of a Lead Specific Chelator (PSC) Conjugated to Radiopeptides for 203Pb and 212Pb-Based Theranostics;Pharmaceutics;2023-01-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3